Vaccines Virtual Conference 2021
DAY 1|5th August 2021
Track A COVID-19 Vaccine & Clinical Trials
Track B Vaccine Design and Pre-Clinical Development
8:50 am Welcome Talk from GlobalData
9:00 am KEYNOTE TALK: Development of the World’s First Triple Antigen Oral SARS Cov-2 Vaccine
- The platforms involved, D-Crypt and POD technologies.
- The idea, prototype and path to development
- The initial experiments and data.
- Road to phase 1 in Humans.
- Breaking the barrier: exploring the possibilities of oral delivery of vaccines
Cofounder & Managing Director
9:30 am Vaccine Clinical Trials from a European Site Perspective
Executive Director, Portfolio Management
10:00 am CASE STUDY: Top 5 Tips On How To Manage A Clinical Trial During A Pandemic?
- Establishing your position with regulatory bodies to ensure you are keeping in line with the current practices
- Assessing current data collected to determine the current steps needed of your study
- Liaising with CRO’s to ensure they can fulfil their duty at hand
- Identifying alternative solutions if your current site is not in operation
- Patient safety first: Reviewing your candidates wellbeing to avoid any health risk
Clinical Operations Head Vaccines
10:30 am Paving the way for the development of effective new vaccines
Australia is highly regarded as a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials. A US Investigational New Drug (IND) submission is not required to initiate FIH clinical trials in Australia and sponsors are attracted to the region for clinical trials due to high quality data which is recognised by global regulatory agencies. Clinical sites across Australia have adapted well to the COVID-19 pandemic, with all top ten clinical sites still open for either on-site or remote monitoring. World class R&D and clinical research, demonstrated by the innovative COVID-19 vaccine studies conducted over the last 12 months, is the reason why Australia has become a preferred destination for early phase clinical trials
Executive Vice President, Business Development
11:00 am Networking Break
11:30 am Revealing the Lessons we Can Learn From This Pandemic to Guide Changes in Public Health Policy and Practice and Social Behaviour to Prevent or Minimize the Impact of the Next Pandemic
- Acting fast is key – early measures to limit virus spread and incentives for people to adhere to isolation
- Continuing the development of new technologies to enable us to respond even more quickly in future
- Questions remaining and who needs to address them
Associate Director, Clinical Research Manager
12:00 pm Unified Platforms: Streamlining your Start-Up and Submission for Expedited Vaccine Trials
- Logistics of expediting vaccine trials
- Solutions for alignment of departments and timeline management
- Overall benefits of a unified platform
Associate Director, IWRS/ RTSM
Axiom Real-Time Metrics
Axiom Real-Time Metrics
Clinical Operations, Partnerships & Regulatory Affairs
12:30 pm The global distribution of the COVID-19 vaccine via airfreight
Cargo Specialist Manager for Europe
IATA – International Air Transport Association
1:00 pm Implications of COVID-19 For a Healthy Vaccines Market
- How has COVID-19 changed and shaped how we define a healthy vaccines market globally?
- Learning from the policies and models that have driven or enabled innovation in COVID-19 vaccines
- Are these policies and models unique to pandemic response? What positive or negative unintended consequences from COVID-19 vaccines are likely to impact the long-term health of the global vaccines market?
- Learning from COVID-19 vaccines, how can a healthy market support equitable access to future novel vaccines?
Head, Global Regulatory Affairs, Health & Wellbeing
1:30 pm KEYNOTE PANEL: What of our second generation COVID-19 vaccines? Is SARS-CoV2 here to stay?
- Anticipating what will happen when more vaccines come to market
- Exploring how different vaccines interact in the immune system
- Will we need new COVID vaccines and boosters annually?
- Vaccine deployment and implementation – how do we deliver billions of vaccines globally?
NHS Vaccines Programme
2:15 pm Close of Conference
10:00 am Uncovering Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
- Exploring overwhelming amount of preclinical data to support the notion that vaccination can control or even eradicate tumours
- Moving forward: the success of a vaccine will depend on our capacity to accurately map the dominant immunosuppressive pathway for each individual patient
- Learning that combining a vaccine with immune checkpoint blockade is an effort in vain when a large part of the tumour has acquired defects in MHC class I presentation
- Understanding the challenge will be to develop technologies that can deliver comprehensive tumour immunomics in a timely and cost-effective fashion
11:00 am Networking Break
11:30 am Vaccinating Against Misinformation
- Misinformation vs disinformation
- Educating HCPs vs the public on misinformation
- Tools to track misinformation in real-time and counter it
- Major sources of vaccine disinformation
- Global examples of social listening strategies
- Amplifying vaccine advocacy voices – how can everyone be part of this?
Founder and CEO
Manufacturing, Supply Chain and Commercialisation
12:30 pm Reducing The Use Of Antimicrobials Through Innovative Universal Subunit Vaccine Platform Design
Chief Scientific Officer
2:30 pm Future Perspectives for Combination Immunotherapies
- What class of combination therapies are most promising? What do the current data tell us? (Conventional Therapy e.g., Chemo/ radiation, Antibody Drug Conjugates, Angiogenesis inhibitors and other targeted therapies etc.)
- Can precision medicine tools help with therapeutic selections?
- Overcoming toxicities of combinations
- Uncovering Intratumoral approaches
- Significant recent and upcoming phase III trials – will they boost the field or set us back?
Associate Director, Infectious Disease
Alexander O’ Leary
Portfolio Director – OCT EMEA and Pharma Packaging & Labelling Global
T: +44 207 936 6690
The Clinical Trials In Vaccines programme is written in collaboration with industry, if you have a case study, idea or just a comment, please contact:
Senior Conference Producer
T: + 44 (0) 2079366 607